ACP3 and adenocarcinoma: Morphologically, they may still resemble adenocarcinomas but show markedly reduced AR activity, loss of luminal markers (e.g., PSA; Prostate Specific Antigen, PAP; Prostatic Acid Phosphatase), and clear signs of epigenetic and transcriptional reprogramming.